Orchard Therapeutics Sets $4.25 Million Price Tag for Leukodystrophy Gene Therapy

1. Orchard Therapeutics has settled on a price of $4.25 million US for its leukodystrophy gene therapy called Lenmeldy.
2. The therapy received approval from the U.S. Food and Drug Administration (FDA) to treat metachromatic leukodystrophy (MLD).
3. Orchard Therapeutics disclosed the price on Wednesday, considering it to reflect the economic and societal value of the one-time treatment.
4. The therapy is indicated for children with MLD, making Lenmeldy the first gene therapy approved in the U.S. for this condition.